Does Saw Palmetto Urinary Symptoms Randomized Trial work?

Updated July 2026

Quick Answer

Saw Palmetto Urinary Symptoms Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: This systematic review assessed the potential effectiveness and safety of Serenoa repens (saw palmetto) for benign prostatic disorders, mainly benign prostatic hyperplasia and associated lower urinary tract symptoms.

Key Takeaways

  • 01This systematic review assessed the potential effectiveness and safety of Serenoa repens (saw palmetto) for benign prostatic disorders, mainly benign prostatic hyperplasia and associated lower urinary tract symptoms. [Schwartzmann I (2026)]
  • 02repens was associated with improvements in symptom severity (International Prostate Symptom Score) in several trials, with variable effects on urinary flow, post-void residual volume, and patient-reported quality of life. [Schwartzmann I (2026)]
  • 03Following PRISMA guidance (PROSPERO: CRD420251032255), we searched PubMed, Cochrane and ScienceDirect for human studies from January 2020 to May 2025. [Schwartzmann I (2026)]
  • 04Conclusions : Although this study was a pilot study with a limited cohort, these findings provide preliminary evidence for the use of SAGX as a functional ingredient for supporting urinary health in men with LUTS. [Kim EY (2026)]
The current Migaku evidence database contains 2 reusable source documents for Saw Palmetto Urinary Symptoms Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - This systematic review assessed the potential effectiveness and safety of Serenoa repens (saw palmetto) for benign prostatic disorders, mainly benign prostatic hyperplasia and associated lower urinary tract symptoms. [Schwartzmann I (2026); evidence level 1] - repens was associated with improvements in symptom severity (International Prostate Symptom Score) in several trials, with variable effects on urinary flow, post-void residual volume, and patient-reported quality of life. [Schwartzmann I (2026); evidence level 1] - Following PRISMA guidance (PROSPERO: CRD420251032255), we searched PubMed, Cochrane and ScienceDirect for human studies from January 2020 to May 2025. [Schwartzmann I (2026); evidence level 1] - Conclusions : Although this study was a pilot study with a limited cohort, these findings provide preliminary evidence for the use of SAGX as a functional ingredient for supporting urinary health in men with LUTS. [Kim EY (2026); evidence level 2] - Background: Lower urinary tract symptoms (LUTS) are prevalent among aging men and negatively affect quality of life. [Kim EY (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Efficacy and safety of Serenoa repens in benign prostatic disorders: a systematic review of recent clinical evidence.
  2. Efficacy and Safety of <i>Salvia miltiorrhiza</i> Extract (SAGX) Compared with Saw Palmetto in Men with Lower Urinary Tract Symptoms: A 12-Week, Randomized, Double-Blind, Parallel-Group Pilot Study.